There is an increased interest in cannabis-derived products for the treatment of human illness. Most recently, randomized and double blinded clinical trials have shown efficacy of plant-derived extract for the treatment of seizures associated with Lennox-Gastaut and Dravet Syndromes.

Jerzy Szaflarski, MD, PhD discusses how concurrent open label studies showed potential efficacy of cannabidiol for the treatment of other seizure types and the utility of cannabis-derived products (FDA approved and artisanal) for the treatment of epilepsy.